Skip to navigation Skip to content

Neurofibromatosis type 1 (NF1) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070423

Expand/Collapse all sectionsExpand all



NF1 restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

https://ourblueprint.internal.dept.local/content/images/icon-hidden-attachment.png|A linked attachment is available for staff only (i.e. under IPS/FOI) PBS NF1 restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Neurofibromatosis type 1 - selumetinib - initial authority application (PB370)

Neurofibromatosis type 1 - selumetinib - initial grandfather authority application (PB371)

Services Australia website

Neurofibromatosis type 1

External websites

PBS schedule for neurofibromatosis type 1

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item

Description

1

Is there an age restriction for patients applying for PBS-subsidised treatment of NF1 under initial or grandfather criteria?

Yes. Patients must be aged between 2 and 18 years:

  • to apply under the initial treatment criteria
  • before starting non-PBS-subsidised treatment for NF1 to apply under the grandfather treatment criteria

2

Is there an age restriction for patients applying for PBS-subsidised treatment of NF1 under continuing criteria?

No. There is no age limitation under continuing criteria.

3

Are questions and answers (Q&A) attached to relevant restrictions of NF1 available in the National Drug Reference Database (NDRD)?

No. NF1 authority applications are assessed by Dynamic Q&A in the Online PBS Authorities (OPA) system.

For troubleshooting, see Resources page > Dynamic Question and Answers (DQA) resources in Dosage calculators and charts for Pharmaceutical Benefits Scheme (PBS).